NASDAQ Healthcare Biotechnology ABEO

Abeona Therapeutics Inc.

$ 5.77 2.12 %

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

CEO: Vishwas Seshadri - https://www.abeonatherapeutics.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$17 194.63 %

Recommandation

Buy

DCF

$ 1.01

Loading data...

ABEO vs S&P500

Loading data...

No data available.

Quick ratio

5.70

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

6.07

may indicate that the company is undervalued or has poor growth prospects.

EPS

0.95

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

41.40 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

-50.87 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

10.86

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.16

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-1.51

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
6 indicates moderate financial health
Altman score
0.48 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.98 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.12 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.